IDEAYA Biosciences, Inc. (IDYA)
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.
Address
5000 SHORELINE CT, SUITE 300
SOUTH SAN FRANCISCO, CA 94080
Founded
2015
Number of Employees
124
Website
http://www.ideayabio.com
Buyback
| Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $ Amount Purchased ($ in 000s) |
- | - | - | - | - | $62,409 | $11 | - | - | - | - | $31,210 |
| Average Price | - | - | - | - | - | $2,633.53 | $1.08 | - | - | - | - | $1,824.31 |
| # Shares Purchased | - | - | - | - | - | 23,698 | 10,518 | - | - | - | - | 17,108 |
| Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Return to Date | - | - | - | - | - | -98.6% | 3,336.7% | - | - | - | - | -98.0% |
| S&P 500 Return to Date | - | - | - | - | - | 93.1% | 74.8% | - | - | - | - | 84.0% |
| Excess Total Return | - | - | - | - | - | -191.7% | 3,261.9% | - | - | - | - | -181.9% |
| Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
| Percentile Rank | - | - | - | - | - | 0% | 100% | - | - | - | - | 0% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
Never miss an email alert when insiders at IDYA make a trade.
Creating a free account takes less than one minute